Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients with colon cancer.
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera’s Empower hereditary cancer test the opportunity for further risk assessment using MyOme’s integrated polygenic risk score.
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company’s clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT).
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting.
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts.
Natera Issues Statement on Guardant Health Litigation
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement:
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that its co-founder and executive chairman, Matthew Rabinowitz, PhD, has been named R&D Leader of the Year by R&D World.
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera.
Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024.
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB (Alliance)/SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal cancer (CRC) in a biomarker unselected population.
Natera to Participate in Upcoming Investor Conferences
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December.
Natera to Report its Third Quarter 2024 Results on November 12, 2024
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Natera to Present New Renasight Data at ASN Kidney Week 2024
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its 385-gene kidney genetic test, Renasight™, at the annual meeting of the American Society of Nephrology (ASN) Kidney Week 2024. The meeting will take place in San Diego from Oct. 23-27.
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics in response to inquiries:
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced the simultaneous publication of three peer-reviewed papers, crossing a milestone of more than 85 peer-reviewed publications on Signatera. This includes:
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC).
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain.
Natera Reports Second Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024.
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA.
Natera to Report its Second Quarter 2024 Results on August 8, 2024
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here.
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA.
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer.
Myriad Genetics Sees Stock Surge with Hereditary Cancer TestsMyriad Genetics Inc. (NASDAQ:
MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
Natera, Inc. (NASDAQ:
NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.
